Loading company
$8.49+0.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 28, 2026
Past performance
- 1W
- -1.3%
- 1M
- -8.2%
- 3M
- -44.7%
- 6M
- -33.6%
- 1Y
- -45.0%
- 5Y
- -48.6%
$8.49+0.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 28, 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $12.1M | $8.9M | +36.27% |
| Profit | -$7.5M | -$5.9M | -26.63% |
| Profit per share | -$0.24 | -$0.21 | -14.29% |
| Free Cash Flow | -$20.2M | -$3.3M | -509.55% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company’s flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from ClearPoint Neuro, Inc.’s Item 2.02 8-K filed October 28, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
ClearPoint Neuro, Inc. has no earnings call transcript available.
Just reported
From ClearPoint Neuro, Inc.'s results release of October 28, 2026; its quarterly report has since been filed.
Actual
$12.1M
+36% y/y
+11% q/q
Guided
—
No guide given
Actual
-$0.24
Guided
—
No guide given
Actual
-$6.3M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.